Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04866485 | A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combined With Anti-PD-1 Antibody | unknown | Phase 1 | 66 | Harbour BioMed (Guangzhou) Co. Ltd.INDUSTRY | 0 | Apr 29, 2021 | clinicaltrials |
| NCT02435927 | ASLAN001 in Combination With Oxaliplatin and Capecitabine or Oxaliplatin and 5-FU With Leucovorin | unknown | Phase 1 | 60 | National Cancer Centre, SingaporeOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT04864379 | Clinical Study of a Personalized Neoantigen Cancer Vaccine Combined With Anti-PD-1 and RFA in Patients With Solid Tumors | unknown | Phase 1 | 30 | Sir Run Run Shaw HospitalOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT04758897 | Clinical Study of VG161 in Subjects With Advanced Malignant Solid Tumors | unknown | Phase 1 | 18 | CNBG-Virogin Biotech (Shanghai) Ltd.INDUSTRY | 1 | Apr 27, 2021 | clinicaltrials |
| NCT04843033 | A Study to Investigate Safety and Tolerability of SH3809 Tablet in Patients With Advanced Solid Tumors | unknown | Phase 1 | 55 | Nanjing Sanhome Pharmaceutical, Co., Ltd.INDUSTRY | 1 | Apr 13, 2021 | clinicaltrials |
| NCT04675060 | Effect of High-fat Meal on the Pharmacokinetics of TQ-B3139 Capsules | unknown | Phase 1 | 12 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 1, 2021 | clinicaltrials |
| NCT04825392 | A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 30 | Taizhou Hanzhong biomedical co. LTDINDUSTRY | 1 | Apr 1, 2021 | clinicaltrials |
| NCT02500199 | Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors | unknown | Phase 1 | 50 | Hengrui Therapeutics, Inc.INDUSTRY | 1 | Feb 1, 2021 | clinicaltrials |
| NCT04727164 | Study Investigating Safety,Tolerability,Pharmacokinetics and Antitumor Activities of HBM4003 Combine With Toripalimab | unknown | Phase 1 | 61 | Harbour BioMed (Guangzhou) Co. Ltd.INDUSTRY | 0 | Jan 29, 2021 | clinicaltrials |
| NCT04699643 | FGFR4 Inhibitor EVER4010001 in Combination With PD-1 Inhibitor Pembrolizumab in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 80 | EverNov Medicines (Zhuhai Hengqin) Co., LtdINDUSTRY | 1 | Jan 7, 2021 | clinicaltrials |
| NCT04325711 | A Study of CSPCHA131 in Patients With Advanced Solid Tumor | unknown | Phase 1 | 100 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jan 6, 2021 | clinicaltrials |
| NCT04689100 | Efficacy and Safety of JMT101 in Patients With Advanced Solid Tumor | unknown | Phase 1 | 259 | Shanghai JMT-Bio Inc.INDUSTRY | 1 | Dec 30, 2020 | clinicaltrials |
| NCT04673396 | Phase I Clinical Study for Evaluation of Pharmacokinetic, Safety, Tolerance of Norcantharidin Lipid Microsphere for Injection in Patients With Solid Tumor | unknown | Phase 1 | 36 | Beijing Nuokangda Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Dec 21, 2020 | clinicaltrials |
| NCT04226066 | Safety, Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC), in Patients With Advanced Malignant Solid Tumors | unknown | Phase 1 / Phase 2 | 69 | Tasly Tianjin Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 7, 2020 | clinicaltrials |
| NCT04478461 | Safety, Tolerability, and Pharmacokinetics of MW11 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 21 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Nov 13, 2020 | clinicaltrials |
| NCT04623892 | A Study to Evaluate the Tolerance and Pharmacokinetics of TQB2618 Injection in Subjects With Advanced Solid Tumors | unknown | Phase 1 | 50 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Nov 10, 2020 | clinicaltrials |
| NCT04262739 | MTD, Safety and Efficacy of NYH817G and NYH100P in Monotherapy and Combination in Patients With Advanced Solid Tumors | unknown | Phase 1 | 42 | Haim Bio Co., Ltd.INDUSTRY | 1 | Oct 20, 2020 | clinicaltrials |
| NCT04588324 | Study of SHR2150 (TLR7 Agonist) in Combination With Chemotherapy Plus PD-1 or CD47 Antibody in Subjects With Unresectable/ Metastatic Solid Tumors | unknown | Phase 1 / Phase 2 | 50 | Chinese PLA General HospitalOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT04550663 | NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors | unknown | Phase 1 | 10 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Sep 23, 2020 | clinicaltrials |
| NCT03545815 | Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors. | unknown | Phase 1 | 10 | Chinese PLA General HospitalOTHER | 1 | Aug 10, 2020 | clinicaltrials |
| NCT04477057 | PhaseⅠStudy of the HS-10241 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 30 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 20, 2020 | clinicaltrials |
| NCT04408079 | A Study to Evaluate the Tolerance, Efficacy and Pharmacokinetics of TQB3558 Tablets | unknown | Phase 1 | 70 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 8, 2020 | clinicaltrials |
| NCT04309968 | Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Anti-tumor Activity of SYHA1801 Monotherapy in Patients With Advanced Solid Tumors | unknown | Phase 1 | 186 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jun 9, 2020 | clinicaltrials |
| NCT04423380 | A Study to Investigate Safety and Tolerability of SH3051 Capsule in Patients With Advanced Solid Tumors | unknown | Phase 1 | 45 | Nanjing Sanhome Pharmaceutical, Co., Ltd.INDUSTRY | 1 | Jun 9, 2020 | clinicaltrials |
| NCT04413227 | A Phase Ib Study With Pegylated Recombinant Human Endostatin in Advanced / Metastatic NSCLC or Other Solid Tumors | unknown | Phase 1 | 30 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 2, 2020 | clinicaltrials |
| NCT03468751 | Phase 1 Study of HLX10, a Monoclonal Antibody Targeting Programmed Death-1 (PD-1) in Patients With Advanced Solid Tumors | unknown | Phase 1 | 30 | Henlix, IncINDUSTRY | 1 | Jun 1, 2020 | clinicaltrials |
| NCT04169178 | Evaluate Safety, Tolerability and PK of HLX55 in Patients With Advanced Solid Tumors With Different cMET Status | unknown | Phase 1 | 98 | Henlix, IncINDUSTRY | 1 | May 1, 2020 | clinicaltrials |
| NCT04360317 | Safety of the Combination of SH003 and Docetaxel in Patients With Solid Cancer | unknown | Phase 1 | 9 | Kyunghee University Medical CenterOTHER | 0 | Apr 24, 2020 | clinicaltrials |
| NCT03950297 | Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A | unknown | Phase 1 | 24 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.INDUSTRY | 1 | Apr 3, 2020 | clinicaltrials |
| NCT03168061 | Dose-Escalation and Expansion Trial of NC-6300 in Patients With Advanced Solid Tumors or Soft Tissue Sarcoma | unknown | Phase 1 / Phase 2 | 150 | NanoCarrier Co., Ltd.INDUSTRY | 1 | Feb 28, 2020 | clinicaltrials |
| NCT04275050 | A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3303 Tablets | unknown | Phase 1 | 40 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Feb 19, 2020 | clinicaltrials |
| NCT03415659 | Phase I Clinical Study of HWH340 Tablet in Patients With Advanced Solid Tumors | unknown | Phase 1 | 85 | Hubei Biological Medicine Industrial Technology Institute Co., Ltd.OTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT03160833 | A Study of HMPL-453 in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 33 | Hutchison Medipharma LimitedINDUSTRY | 1 | Feb 13, 2020 | clinicaltrials |
| NCT04228406 | Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy Evaluation of GST-HG161 | unknown | Phase 1 | 62 | Fujian Cosunter Pharmaceutical Co. LtdINDUSTRY | 1 | Jan 14, 2020 | clinicaltrials |
| NCT04151329 | A Phase I Clinical Trial of BAT1306 and BAT8001 Injection in Patients With Solid Tumor | unknown | Phase 1 / Phase 2 | 72 | Bio-Thera SolutionsINDUSTRY | 1 | Nov 5, 2019 | clinicaltrials |
| NCT04143789 | Evaluation of AP-002 in Patients With Solid Tumors | unknown | Phase 1 / Phase 2 | 61 | Altum Pharmaceuticals INCINDUSTRY | 1 | Oct 31, 2019 | clinicaltrials |
| NCT03897283 | Study of TQB2450 Combined With Anlotinib in Patients With Advanced Solid Tumors | unknown | Phase 1 | 22 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Oct 30, 2019 | clinicaltrials |
| NCT04144855 | A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3474 Injection | unknown | Phase 1 | 40 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Oct 30, 2019 | clinicaltrials |
| NCT02963168 | A DRF Study to Evaluate Safety, Tolerability, PK, and Activity of Oradoxel Monotherapy in Subjects w Adv. Malignancies | unknown | Phase 1 | 24 | Athenex, Inc.INDUSTRY | 1 | Oct 17, 2019 | clinicaltrials |
| NCT03879057 | Trial of Surufatinib Combined With JS001 in the Treatment of Advanced Solid Tumors | unknown | Phase 1 | 24 | Peking UniversityOTHER | 1 | Oct 1, 2019 | clinicaltrials |
| NCT03583125 | Study of EOC317 in Chinese Patients With Advanced Solid Tumors | unknown | Phase 1 | 140 | Taizhou EOC Pharma Co., Ltd.INDUSTRY | 1 | Sep 11, 2019 | clinicaltrials |
| NCT03991559 | A Safety Study of the Pan-immunotherapy in Patients With Unresectable/Metastatic Solid Tumors or Lymphomas | unknown | Phase 1 | 20 | Chinese PLA General HospitalOTHER | 1 | Aug 28, 2019 | clinicaltrials |
| NCT04049929 | A Phase I Study of YY-20394 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 50 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 1 | Aug 8, 2019 | clinicaltrials |
| NCT03641794 | Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers | unknown | Phase 1 | 56 | Jiangxi Qingfeng Pharmaceutical Co. Ltd.INDUSTRY | 1 | Aug 1, 2019 | clinicaltrials |
| NCT02575638 | Safety Study of Camptothecin-20-O-Propionate Hydrate (CZ48) | unknown | Phase 1 | 65 | Cao Pharmaceuticals Inc.INDUSTRY | 1 | Jul 23, 2019 | clinicaltrials |
| NCT04001569 | AZD8186 and Paclitaxel in Advanced Gastric Cancer | unknown | Phase 1 / Phase 2 | 49 | Seoul National University Bundang HospitalOTHER | 1 | Jun 28, 2019 | clinicaltrials |
| NCT03757936 | A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Anti-PD-1 Antibody (HLX10) in Combination With Avastin Biosimilar (HLX04) in Patients With Advanced Solid Tumors | unknown | Phase 1 | 30 | Shanghai Henlius BiotechINDUSTRY | 1 | May 23, 2019 | clinicaltrials |
| NCT03940820 | Clinical Research of ROBO1 Specific CAR-NK Cells on Patients With Solid Tumors | unknown | Phase 1 / Phase 2 | 20 | Asclepius Technology Company Group (Suzhou) Co., Ltd.INDUSTRY | 1 | May 7, 2019 | clinicaltrials |
| NCT02414516 | A Dose-Escalation Study of OBP-801 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 17 | Oncolys BioPharma IncINDUSTRY | 1 | Mar 13, 2019 | clinicaltrials |
| NCT03844438 | A Study Evaluating the Safety, Tolerability of LPM3480226 Tablets in Patients With Advanced Solid Tumors | unknown | Phase 1 | 30 | Luye Pharma Group Ltd.INDUSTRY | 1 | Feb 20, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Apr 29, 2021source: clinicaltrials